« Back
Home /
AR Peptide - N-terminal region (AAP30974)

AR Peptide - N-terminal region (AAP30974)

Item no.	AAP30974
Manufacturer	AVIVA Systems Biology
Amount	100 ug
Category	Oncology Neuroscience Neural Lineage Markers Metabolism Diabetes Regulation of Appetite Neural Transcription Factors Molecular Targets for Neuroscience Targets for Rodent Neurosciences Aging & Neurological Disorders Neural Signaling Neural Epigenetics Protein Aggregation, Clearance & Misfolding Neural Development Neural Adhesion Molecules By Cell Type Carcinoma Peptides & Proteins Western Blot Peptides By Organ Bladder Cancer Glial Cell Markers
Type	Peptides
Format	Lyophilized powder
Applications	WB
Specific against	other
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	AIS, DHTR, HUMARA, KD, NR3C4, SBMA, SMAX1, TFM
Similar products	AR
Available
Description	This is a synthetic peptide designed for use in combination with anti-AR antibody (Catalog #: ARP30974_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Gene symbol	AR
Protein size	920
Molecular weight	99kDa
Product format	Lyophilized powder
Gene id	367
Reconstitution and storage	Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20C. Avoid repeat freeze-thaw cycles.
Partner proteins	AKT1, CASP1, CASP3, CASP7, CASP8, CAV1, FGF8, KLK2, KLK3, NCOA1, NCOA1, NCOA2, RB1, TGFB1I1, AES, AHR, AKT1, APOL2, APPBP2, AR, ATF2, BAG1, BRCA1, CALM1, CALR, CASP1, CASP3, CASP7, CASP8, CAV1, CCND1, CCNE1, CCNH, CDC25A, CDC25B, CDC37, CDK1, CDK6, CDK7, CDK9, COX5B, CREBBP, CTDSP2, CTNNB1, CUL4B, DAP3, DAXX, DCAF6, DDC, EFCAB6, EGFR, EP300, ESR1, ETV5, FHL2, FLNA, FOXA1, FOXO1, GAK, GAPDH, GNB2L1, GRIP1, GSK3B, GSN, GTF2F1, GTF2F2, GTF2H1, HDAC1, HIF1A, HIPK3, HMGB1, HSP90AA1, IARS, IDE, IFI16, IL6ST, JMJD1C, JUN, KAT2B, KAT5, KDM1A, KIF1A, KLK2, MAPK1, MDM2, MED1, MED14, MYBBP1A, MYST2, NCOA1, NCOA2, NCOA3, NCOA4, NCOR1, NCOR2, NFKB1, NISCH, NONO, NR0B1, NR0B2, NR2C1, NR2C2, NR3C1, NR3C2, NR5A1, NRIP1, NSD1, PA2G4, PAK6, PIAS1, PIAS2, PIAS3, PIAS4, PNRC1, PNRC2, POU2F1, POU5F1, PRMT1, PSMC3IP, PTEN, PXN, RAC3, RAD54L2, RAD9A, RAF1, RAN, RANBP9, RB1, RBAK, RCHY1, RELA, RNASEL, RNF14, RNF4, RUNX1, RUNX2, SART3, SLC25A4, SMAD1, SMAD3, SMAD4, SP1, SPDEF, SRC, SRY, STAT3, STUB1, SUMO1, SVIL, TCF4, TGFB1I1, TGIF1, TMF1, TRIM24, TRIP4, TSG101, UBE2I, UBE3A, UXT, WIPI1, XRCC5, XRCC6, ZMIZ1, AES, AKT1, AR, BAG1, BRCA1, CALM1, CALR, CAV1, CCND1, CCNE1, CCNH, CDC25B, CDC37, CDK7, CDK9, CEBPA, CEBPB, COX5B, CREBBP, CTNNB1, DAP3, DAXX, DCC, EFCAB6, EGFR, ETV5, FHL2, FLNA, FOXA1, FOXO1, GAPDH, GNB2L1, GRIP1, GSK3A, GSK3B, GSN, GTF2F1, GTF2F2, GTF2H1, HDAC1, HDAC3, HDAC4, HMGB1, HMGB2, HNF4A, HSP90AA1, HSPA1A, HSPB2, IL6ST, JUN, KAT5, MAGEA11, MAPK1, MDM2, MED1, MYST2, NCOA1, NCOA2, NCOA3, NCOA4, NCOA6, NCOR1, NCOR2, NONO, NR0B1, NR0B2, NR2C1, NR2C2, NSD1, PA2G4, PAK6, PATZ1, PELP1, PIAS1, PIAS2, PIAS3, PIAS4, PMEPA1, POU2F1, POU2F2, PRKDC, PRMT1, PRPF6, PSPC1, PTEN, RAD9A, RAF1, RAN, RANBP9, RB1, RCHY1, RNF14, RNF4, SART3, SELENBP1, SMAD3, SMAD4, SMARCA4, SMARCC1, SP1, SPDEF, SRC, SRY, STAT3, SVIL, TBP, TCF4, TDG, TGFB1I1, TMF1, TP53, TRIM24, TRIM68, TSG101, UBC, UBE2I, UXT, XRCC5, XRCC6, YWHAQ, ZMIZ1
Description of target	AR has 3 major functional domains: the N-terminal domain, DNA-binding domain, and androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. This gene contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of its protein. Expansion of the polyglutamine tract causes spinal bulbar muscular atrophy (Kennedy disease). Mutations in this gene are also associated with complete androgen insensitivity (CAIS).The androgen receptor gene is more than 90 kb long and codes for a protein that has 3 major functional domains: the N-terminal domain, DNA-binding domain, and androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. This gene contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of its protein. Expansion of the polyglutamine tract causes spinal bulbar muscular atrophy (Kennedy disease). Mutations in this gene are also associated with complete androgen insensitivity (CAIS). Two alternatively spliced variants encoding distinct isoforms have been described.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

AAP30974-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 100 ug

available

Delivery expected until 10/30/2025

Express Delivery: Save 20 days

Compare

Add to wishlist

Get an offer